{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-004835","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.426465+00:00","generated_at":"2026-05-31T09:32:53.716274+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VolitionRx Q2 revenue up 83% to $396K; H1 test sales exceed full-year 2023","bullets":["Q2 revenue $396K (+83% YoY); H1 revenue $567K (+55% YoY).","Operating expenses down 24% YoY in Q2; targeting $10M annualized cost reductions.","Cash $6.0M at June 30; closed $7M registered direct offering with up to $14.5M in milestone-linked warrants.","Sold over 60,000 Nu.Q Vet Cancer Tests in H1 2024 (vs 58,000 full-year 2023); now available in 17 countries.","Engaged PharmaVentures to advise on licensing deals for Nu.Q Cancer and Capture-PCR."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-004835","json":"https://secwatch.observer/filing/0001477932-24-004835.json","markdown":"https://secwatch.observer/filing/0001477932-24-004835.md","text":"https://secwatch.observer/filing/0001477932-24-004835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793224004835/0001477932-24-004835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793224004835/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:32:53.716274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}